# Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

> **NCT01029652** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 230 (actual)

## Conditions studied

- Acute Gout

## Interventions

- **DRUG:** Canakinumab 150 mg
- **DRUG:** Triamcinolone acetonide 40 mg
- **DRUG:** Placebo to canakinumab
- **DRUG:** Placebo to triamcinolone acetonide

## Key facts

- **NCT ID:** NCT01029652
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2014-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029652, "Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01029652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*